Disclosed herein are embodiments of a composition comprising at least three layers. Layers one and two each either comprises a sensitizer or an emitter, typically a metal ion or a dye, and the third layer may or may not comprise a sensitizer or emitter. Upon exposure to light, such as infrared light, the composition produces visible and/or UV light. The composition may further comprise a capping moiety, a therapeutic agent, an uptake enhancer, a detection moiety that binds to a desired target, a quenching moiety, or a combination thereof. The composition may be a particle, such as a nanoparticle, or it may be a planar composition. Also disclosed are embodiments of a method for using the composition, including, but not limited to, a method for delivering a therapeutic agent, or a method for detecting a target, such as a biological target.

Exemplary methods, systems and computer-accessible medium for detecting at least one condition of at least one disease. In particular, it is possible to administer at least one composition to at least one patient, where the at least one composition includes at least one bond-edited compound configured to target at least one of a disease tissue or a pathogen. Further, it is possible to receive information related to the administration of the composition to the patient. It is also possible to detect the at least one bond-edited compound using a Raman scattering arrangement.

The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.

A system for quantifying the presence of at least one chemical and/or a physical condition in ocular tissues is provided. The system uses a membrane having at least one photo-reactive chemical- and/or physical condition-sensing indicator dye and a photo-reactive reference dye wherein both the photo-reactive chemical- and/or physical condition-sensing indicator dye and the photo-reactive reference dye are responsive to the same wavelength of an excitation light source but emit different wavelengths of light in a light spectrum. An optical data detector receives the emitted light and a processor splits the data into two or more colours of the light spectrum and measures the intensity of the two or more colours. The colour intensity belonging to the emitted light from the chemical- and/or physical condition-sensing indicator dye is compared to the colour intensity of the light emitted from the reference dye and the amount of chemical present and/or the extent of physical condition is ratiometrically determined therefrom.

The present invention provides a luminogenic, in particular a phosphorogenic transition metal-based pyridyl complex containing a nitrone moiety, which nitrone moiety acts as a bioorthogonal functional group and an emission quencher, and can undergo cycloaddition reaction with a complementary bioorthogonal functional group coupled to a substrate. The transition metal is can be selected from iridium or ruthenium. Also disclosed is a method for preparing the transition metal-based pyridyl complex and a pharmaceutical composition comprising it. Still further provided is a method for bioorthogonal labeling of a biomolecule, a method for staining of a cell structure, a method for in vivo imaging of an organism, and a kit for in vivo imaging of an organism. The luminogenic properties and high reactivity of the complexes are highly advantageous for bioorthogonal labeling and imaging of biomolecules in their native biological environments at much lower costs than those of the existing commercial products.

Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods from making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.

Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Embodiments of the present disclosure provide for radionuclide probes, methods of using the radionuclide probes, methods of detecting an optical signal from radionuclides, methods of detecting an optical signal from a quantum dot(s) that receives optical energy from a radionuclide(s), system for analyzing optical energy emitted by a radionuclide(s), system for imaging a target within a living subject or a sample, methods of imaging a disease or condition, and the like.

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.